A certain type of business quietly succeeds for a very long time without ever quite becoming well-known. Among them is Fisher & Paykel Healthcare. There’s a good chance that a patient is connected to one of the hospital’s breathing circuits or humidifiers if you walk into an intensive care unit anywhere in the developed world. The stock has been increasing shareholder wealth for decades from a corner of Auckland that most foreign investors couldn’t find on a map, despite the brand hardly being recognized outside of the medical community.
Depending on which exchange you examine, the current numbers present two somewhat different narratives. On the final trading day of April, shares on the NZX closed at 36.55 NZD, up a slight 0.83 percent. The Sydney listing, which has dropped more than 11% over the last three months and is hovering around 29.82 AUD, presents a more positive picture. The company operates in two markets and two investor cultures, and the moods don’t always coincide, so it’s the kind of split that counts.
The controversy surrounding the stock is what makes it truly intriguing right now. Midway through April, JPMorgan made an Overweight call to start coverage. Citing a 47 percent premium to fair value, Morningstar advised investors to steer clear of it after examining the same balance sheet. They can’t both be correct. Or perhaps both can, in a sense; this is typically the case with businesses that trade at almost fifty times their earnings.
| Fisher & Paykel Healthcare — Key Information | |
|---|---|
| Company Name | Fisher & Paykel Healthcare Corporation Limited |
| Ticker Symbols | FPH (NZX), FPH (ASX), FSPKF (OTC) |
| Founded | 1934 |
| Founder | Woolf Fisher |
| Headquarters | Auckland, New Zealand |
| CEO | Lewis G. Gradon (since April 2016) |
| Employees | 7,412 (2025) |
| Industry | Medical Instruments & Supplies |
| Share Price (NZX) | 36.55 NZD (30 April 2026) |
| Market Capitalisation | ~20.98B NZD |
| P/E Ratio (TTM) | 49.44 |
| 52-Week Range | 33.05 – 41.40 NZD |
| Dividend Yield | 1.18% |
| Next Earnings Date | 25 May 2026 |
| Countries Sold In | ~120 worldwide |
| Stock Exchange Listings | NZX, ASX, OTC Markets |
Recalling the trajectory is beneficial. Founded in 1934, the company began as an importer of appliances before splitting off its healthcare division, which now forms the core of its identity. Since 2016, Lewis Gradon, an engineer who joined in 1983 and advanced through the product side, has served as chief executive. The lengthy apprenticeship, the engineer in charge, and the modest public persona are all distinctively Kiwi. Gradon is not featured on the cover of business publications. He simply continues to ship goods into the 120 nations where the business currently conducts business.
The market is still processing the complexity of the pandemic years. Respiratory equipment demand skyrocketed. Then it didn’t. Last year, Simply Wall St published a number of slightly concerned articles about whether earnings were keeping up with the share price, inventory increased, and capital efficiency ratios appeared more hazy. Reasonable queries. The trailing P/E is close to 49, earnings per share are at 0.74, and the gross margin of 63.4 percent is the kind of number that explains why long-term holders won’t sell, but it doesn’t quite support the multiple on its own.
As this develops, it seems as though the institutional crowd has made up its mind. Institutions own about 53% of the business. When the story becomes dull, that type of register both caps the upside and smoothes out volatility. The forward yield is approximately 1.19 percent, and the dividend has now been increased twelve times in a row, a run that is nearly embarrassing for a New Zealand company to publicly acknowledge. That’s not why you would purchase it. However, the rationale behind holding it through a quiet period.
Nobody is unaware of the larger context. Through 2035, the global market for anesthesia and respiratory devices is expected to grow at a rate of about 5.8% per year, eventually reaching a value of more than $100 billion USD. Fisher & Paykel is a slow-burning growth story in the sleep apnea market, where it faces off against ResMed and Philips. Although the consumer tech giants have so far shown more interest in tracking sleep than treating it, the fact that Apple and Alphabet are frequently mentioned in the same paragraph as the medical incumbents indicates where the analysts believe the threat lies.
It’s difficult to ignore the fact that Fisher & Paykel doesn’t really fit any of the widely used models. This isn’t a moonshot. Deep value is not what it is. It’s not even very inexpensive. What it is is a business that has been successful at one thing for a very long time, and the market has had decades to price that consistency. It’s still unclear if the upcoming decade will reward patient holders in the same manner as the previous one. Some of it might be addressed in the May earnings call. Most likely not.
